Kathleen Kelly

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5091587/publications.pdf

Version: 2024-02-01

30 papers	2,013 citations	236925 25 h-index	454955 30 g-index
46 all docs	46 docs citations	46 times ranked	3402 citing authors

#	Article	IF	Citations
1	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	7.0	200
2	CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood, 2005, 105, 2836-2844.	1.4	179
3	A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clinical Cancer Research, 2018, 24, 4332-4345.	7.0	154
4	LPA Receptor Heterodimerizes with CD97 to Amplify LPA-Initiated RHO-Dependent Signaling and Invasion in Prostate Cancer Cells. Cancer Research, 2011, 71, 7301-7311.	0.9	144
5	Critical and Reciprocal Regulation of KLF4 and SLUG in Transforming Growth Factor Î²-Initiated Prostate Cancer Epithelial-Mesenchymal Transition. Molecular and Cellular Biology, 2012, 32, 941-953.	2.3	141
6	Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration. Cell Reports, 2018, 23, 808-822.	6.4	111
7	Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone. Molecular and Cellular Biology, 2007, 27, 7538-7550.	2.3	101
8	EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene, 2019, 38, 6241-6255.	5.9	93
9	Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal Transition. American Journal of Pathology, 2011, 179, 422-435.	3.8	85
10	Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell Reports, 2015, 13, 2147-2158.	6.4	74
11	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications, 2021, 12, 1979.	12.8	70
12	Characterizing the Contribution of Stem/Progenitor Cells to Tumorigenesis in thePtenâ^'/â^'TP53â^'/â^' Prostate Cancer Model. Stem Cells, 2010, 28, 2129-2140.	3.2	63
13	Prostate cancer and metastasis initiating stem cells. Cell Research, 2008, 18, 528-537.	12.0	54
14	Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis. Molecular and Cellular Biology, 2015, 35, 1940-1951.	2.3	49
15	TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation. PLoS ONE, 2012, 7, e41668.	2.5	48
16	Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer. Cancer Research, 2010, 70, 8662-8673.	0.9	46
17	Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clinical and Experimental Metastasis, 2009, 26, 403-414.	3.3	45
18	CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Reports, 2019, 29, 2355-2370.e6.	6.4	45

#	Article	IF	Citations
19	The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma. Oncogene, 2001, 20, 3217-3225.	5.9	42
20	AR-Regulated TWEAK-FN14 Pathway Promotes Prostate Cancer Bone Metastasis. Cancer Research, 2014, 74, 4306-4317.	0.9	37
21	Self-Renewing Pten-/-TP53-/- Protospheres Produce Metastatic Adenocarcinoma Cell Lines with Multipotent Progenitor Activity. PLoS ONE, 2011, 6, e26112.	2.5	36
22	Improved Antibacterial Host Defense and Altered Peripheral Granulocyte Homeostasis in Mice Lacking the Adhesion Class G Protein Receptor CD97. Infection and Immunity, 2007, 75, 1144-1153.	2.2	35
23	The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. Clinical Cancer Research, 2019, 25, 6206-6216.	7.0	34
24	Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. Molecular Cancer Therapeutics, 2020, 19, 1436-1447.	4.1	31
25	High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific Reports, 2018, 8, 17239.	3.3	29
26	Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget, 2017, 8, 77181-77194.	1.8	25
27	Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTENâˆ’/âˆ’/p53âˆ’/âˆ’ Prostate Cancer Cells In Vitro and Ex Vivo. Chinese Journal of Integrative Medicine, 2018, 24, 109-116.	1.6	18
28	Reprogramming to resist. Science, 2017, 355, 29-30.	12.6	15
29	TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence. Cancer Gene Therapy, 2022, 29, 1463-1476.	4.6	2
30	Profiling prostate biology. Science, 2020, 368, 467-468.	12.6	0